Day: April 30, 2024

Company Announcement No. 1105 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price   Amount DKK             1: 24 April 2024 70,000   1,028.87   72,020,9002: 25...

Copenhagen, April 30, 2024 (GLOBE NEWSWIRE) — Announcement no. 6-2024 Hypefactors, providing users with a real-time overview to reputation and trust metrics for companies, brands, competitors, industries, and trends, is pleased to announce an investment (private placement) of DKK 2.0 million. The share price for the capital increase is DKK 3.193, which is ten days closing price average minus a 10% discount. The total number of new shares to be issued is 626,370, increasing the total number of shares from 11,443,728 to 12,070,098. This financial action benefits the company’s capital structure directly.Important reminder for all shareholders: Last day of trading is May 14As previously announced, Hypefactors will be delisted from Nasdaq First North Growth Market. A decision that was backed by 98.44% of shareholders vote. All shareholders...

Presented are Utenos trikotažas AB annual Consolidated and Company‘s financial statements for the year 2023 (audited annual financial statements together with auditor‘s report, annual report, confirmation of the responsible persons) approved by the Annual General Meeting of Utenos trikotažas AB shareholders on 30 April 2024.  Managing Director Utenos trikotažas AB Nomeda Kaučikienė AttachmentsUT Audito isvada EN_pasirašytaabutenostrikotazas-2023-12-31-en

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (TSX: FVI) (NYSE: FSM) announced today that the Toronto Stock Exchange has approved the renewal of Fortuna’s normal course issuer bid (the “NCIB”) to purchase up to five percent of its outstanding common shares. Under the NCIB, purchases of common shares may be made through the Toronto Stock Exchange, the New York Stock Exchange and/or alternative Canadian trading systems. The share repurchase program starts on May 2, 2024 and will expire on the earlier of:May 1, 2025; one calendar year after the renewal of the share repurchase program; the date Fortuna acquires the maximum number of common shares allowable under the NCIB; or the date Fortuna otherwise determines not to make any further repurchases under the NCIB.Fortuna believes that from...

BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™. “The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, President and CEO of Xtant Medical. “We expect our new product launches and robust product pipeline will position Xtant as a leader and innovator in the field of advanced biologic therapies.” SimpliGraft and SimpliMax are dehydrated, terminally irradiated, single and dual-layer amniotic membrane sheets intended to serve as a barrier and provide protective coverage...

SHANGHAI, China and SANTA CLARA, Calif., April 30, 2024 (GLOBE NEWSWIRE) — Neusoft Reach Automotive Technology (Shanghai) Co., Ltd., a subsidiary of Neusoft specializing in intelligent vehicle technology, and Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, announced the establishment of a strategic partnership at the Beijing Auto Show. This cooperation is based on the strong resources and advantages of both parties in areas such as automotive software, autonomous driving technology, electrification, and AI system-on-chip (SoC) products. Through this strategic partnership, the companies plan to jointly promote and explore product technology and market development and realize shared opportunities for collaborative innovation and development.Photo: From left to right, Yongfeng Wang, chairman of Neusoft Reach; Wei...

      Share Buyback Transaction Details April 25 – April 29, 2024 April 30, 2024 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 100,546 of its own ordinary shares in the period from April 25, 2024, up to and including April 29, 2024, for 14.1 million and at an average share price of €140.32. The previously disclosed third-party agreement to repurchase shares for €205 million during the period starting February 23, 2024, up to and including April 29, 2024, has hereby been fulfilled. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024 to date 2,488,263 353.0 141.86Repurchased...

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL AVIV, ISRAEL (April 30, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), disclosed today that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration...